Skip to main content
Company profile
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc.

Pipeline4 assets

  • AvexitideGLP-1 receptor / GLP-1 receptor antagonist / Endocrine/metabolic diseases
    Post-bariatric hypoglycemia (PBH)Phase 3LUCIDITY completed enrollment; topline data expected Q3 2026USCongenital hyperinsulinism (HI)Clinical development next steps under discussionUS
  • AMX0035AMX0035 / ER stress and mitochondrial dysfunction / Oral fixed-dose combination of sodium phenylbutyrate and taurursodiol / Neurodegenerative/rare diseases
    Wolfram syndromePhase 2HELIOS positive Week 48 data; pivotal Phase 3 planned pending FDA alignmentUSEU
  • AMX0114AMX0114 / Calpain-2 (CAPN2) / Antisense oligonucleotide (ASO) / Neurodegenerative diseases
    Amyotrophic lateral sclerosis (ALS)Phase 1LUMINA Cohort 2 fully enrolled; biomarker data expected H1 2026US
  • AMX0318AMX0318 / GLP-1 receptor / Long-acting GLP-1 receptor antagonist / Endocrine/metabolic diseases
    PBH and other rare diseasesIND-enablingIND-enabling studies underway; IND targeted for 2027

Latest news16 items

All news

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting

Late-breaking oral presentation to feature Phase 3 topline data highlighting avexitide’s efficacy and safety CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 6, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced it will present two presentations at the upcoming

Presentation / Abstract • Phase 3ObesityWeek late-breaking oral presentation Sun, Nov 15, 2026, 8:30 AM ET

Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

LUCIDITY met FDA -agreed-upon primary endpoint; avexitide demonstrated a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared to placebo (p=0.000003) LUCIDITY met all secondary endpoints showing consistent, highly statistically significant, and clinically

Trial Results • Phase 3Topline results Tue, Aug 18, 2026, 8:00 AM ET

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated in late August or early September 2026 Cash runway expected to fund operations into 2028

Enrollment • Phase 3

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2026-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced the presentation of data from its first-in-human, dose-ranging Phase 1 LUMINA trial of AMX0114 at the European Network to Cure ALS (ENCALS) Meeting 2026, held

Presentation / Abstract • Phase 1Poster presentation Wed, Jun 24, 2026, 5:20 PM CEST

Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 8, 2026-- Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago, IL.

Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results

Topline data readout from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia on track; anticipated in Q3 2026 Cash runway expected to fund operations through potential avexitide commercialization and into 2028 Management to host conference call and webcast today at 8:00

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 6, 2026-- Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in the following upcoming investor conferences, which are being conducted in-person: Bank of America’s 2026 Health Care

Amylyx Pharmaceuticals, Inc. • Endpoint Arena